 | Up a level |
2022
Buisseret, L., Loirat, D., Aftimos, P. G., Punie, K., Maurer, C., Debien, V., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., van den Mooter, T. F. A., Ferrero, J-M., Bonnefoi, H., Canon, J-L., Duhoux, F. P., Bazan, F., Kristanto, P., de Azambuja, E., Ignatiadis, M. and Piccart, M. (2022). Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). Ann. Oncol., 33 (7). S. S1385 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Maurer, C., Agostinetto, E., Ameye, L., Lambertini, M., Martel, S., Ponde, N. F., Brandao, M., Poggio, F., Ferreira, A. R., Schiff, R., De Angelis, C., Gelber, R. D., Dent, S., Thomssen, C., Piccart, M. and de Azambuja, E. (2022). Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial. Ann. Oncol., 33. S. S154 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Metellus, P., Peters, S., Hong, Y-K, Winkler, F., Schadendorf, D., van den Bent, M., Seoane, J., Stahel, R., Minniti, G., Wesseling, P., Weller, M. and Preusser, M. (2021). EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann. Oncol., 32 (11). S. 1332 - 1348. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Morgan, G., Tagliamento, M., Lambertini, M., Devnani, B., Westphalen, B., Dienstmann, R., Bozovic-Spasojevic, I, Calles, A., Criscitiello, C., Curioni, A., Garcia, A. M., Lamarca, A., Pilotto, S., Scheffler, M., Strijbos, M., Wong, R., de Azambuja, E. and Peters, S. (2021). Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. ESMO Open, 6 (2). AMSTERDAM: ELSEVIER. ISSN 2059-7029
2020
Eiger, D., Maurer, C., Brandao, M., Aftimos, P. G., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J-L., Duhoux, F., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart, M. and Buisseret, L. (2020). First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann. Oncol., 31. S. S386 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041